141 related articles for article (PubMed ID: 36163560)
41. Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma.
Chen Y; Yang Y; Ma L; Zhu H; Feng T; Jiang S; Wei Y; Wang T; Sun X
Eur J Radiol; 2019 Mar; 112():44-51. PubMed ID: 30777218
[TBL] [Abstract][Full Text] [Related]
42. Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series.
Liu C; Liu C; Zou X; Shao L; Sun Y; Guo Y
Diagn Pathol; 2021 Mar; 16(1):21. PubMed ID: 33706781
[TBL] [Abstract][Full Text] [Related]
43. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
44. Mutation Spectrum of
Mao L; Zhao W; Li X; Zhang S; Zhou C; Zhou D; Ou X; Xu Y; Tang Y; Ou X; Hu C; Ding X; Luo P; Yu S
Pathol Oncol Res; 2021; 27():602726. PubMed ID: 34257561
[TBL] [Abstract][Full Text] [Related]
45. Fance deficiency inhibits primordial germ cell proliferation associated with transcription-replication conflicts accumulate and DNA repair defects.
Zhou Z; Yin H; Suye S; Ren Z; Yan L; Shi L; Fu C
J Ovarian Res; 2023 Aug; 16(1):160. PubMed ID: 37563658
[TBL] [Abstract][Full Text] [Related]
46. Evaluating the Patient With a Pulmonary Nodule: A Review.
Mazzone PJ; Lam L
JAMA; 2022 Jan; 327(3):264-273. PubMed ID: 35040882
[TBL] [Abstract][Full Text] [Related]
47. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J
BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657
[TBL] [Abstract][Full Text] [Related]
48. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
49. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
50. Next-generation sequencing analysis identifies genomic alterations in pathological morphologies: A case of pulmonary carcinosarcoma harboring EGFR mutations.
Koba H; Kimura H; Nishikawa S; Sone T; Abo M; Hara J; Hosomichi K; Tajima A; Kasahara K
Lung Cancer; 2018 Aug; 122():146-150. PubMed ID: 30032823
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
[TBL] [Abstract][Full Text] [Related]
52. Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review.
Cheng YI; Gan YC; Liu D; Davies MPA; Li WM; Field JK
BMC Cancer; 2019 Nov; 19(1):1068. PubMed ID: 31703574
[TBL] [Abstract][Full Text] [Related]
53. Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
Trabelsi Grati O; Zemoura L; Nhy C; Daniel C; Melaabi S; Callens C; Gauthier Villars M; Bièche I; Girard N
Lung Cancer; 2022 Dec; 174():186-187. PubMed ID: 36156246
[TBL] [Abstract][Full Text] [Related]
54. Insights into Fanconi Anaemia from the structure of human FANCE.
Nookala RK; Hussain S; Pellegrini L
Nucleic Acids Res; 2007; 35(5):1638-48. PubMed ID: 17308347
[TBL] [Abstract][Full Text] [Related]
55. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib.
Ding PN; Becker T; Bray V; Chua W; Ma Y; Xu B; Lynch D; de Souza P; Roberts T
Thorac Cancer; 2019 Oct; 10(10):1879-1884. PubMed ID: 31414729
[TBL] [Abstract][Full Text] [Related]
56. Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With
Lin X; Peng M; Chen Q; Yuan M; Chen R; Deng H; Deng J; Liu O; Weng Y; Chen M; Zhou C
Front Oncol; 2021; 11():774156. PubMed ID: 34869019
[TBL] [Abstract][Full Text] [Related]
57. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
58. [Diffuse pulmonary meningotheliomatosis: a case report and literature review].
Ding YL; Zhu H; Yang W; Liu BB; Zhu X; Li MJ; He B
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Jan; 42(1):24-29. PubMed ID: 30630245
[No Abstract] [Full Text] [Related]
59. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
60. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
